jbm > Volume 31(3); 2024 > Article
Ha, Kim, and Yoo: Open, Active-Controlled Clinical Study to Evaluate the Correlation between Whole Body DEXA and BIA Muscle Measurements

Abstract

Background

Dual energy X-ray absorptiometry (DXA) is the gold standard for diagnosing sarcopenia. However, comparative studies using bioelectrical impedance analysis (BIA) would be required in the Korean population. This study aimed to evaluate the correlation between total-body bone density measuring devices (Hologic and GE Lunar) and a bioelectrical impedance measurement device (InBody 970) as well as the correlation between upper body muscle mass.

Methods

A total of 119 participants were involved in this study, aged 20 to 70 years, with specific body mass index ranges and no severe health conditions used both DXA (or DEXA) and BIA technologies to assess body composition. The participants were scanned using a Hologic QDR-4500W DXA scanner and GE-Lunar Prodigy DXA systems, and the InBody 970 type of multi-frequency BIA machine. Statistical analysis was performed to determine the correlation between the devices, with a coefficient of at least 0.8.

Results

The muscle mass measurement comparisons between the InBody 970 and Hologic devices demonstrated remarkably high correlation coefficients (exceeding 0.9) across all limbs. Similarly, the muscle mass comparison between the Inbody 970 and GE Lunar devices also revealed substantial correlation coefficients, ranging from 0.83 upwards, across all limbs.

Conclusions

Limb muscle mass measurements using Hologic and GE Lunar whole-body DXA and Inbody 970 BIA demonstrated particularly high levels of concordance. In addition, a conversion formula that bridges limb muscle mass measurements from two widely used whole-body DXA machines and a BIA machine will facilitate sarcopenia research and patient management.

GRAPHICAL ABSTRACT

INTRODUCTION

Sarcopenia is characterized by a decrease in muscle mass and physical function with age and increases the risk of frailty, disability, falls, fractures, and death. As the average lifespan of Koreans continues to increase and the aging population accelerates, it is estimated that approximately 700,000 to 1 million elderly individuals over 65 years of age are affected by sarcopenia.[1-4] This condition is emerging as a significant health issue that escalates medical and long-term care costs, especially in a super-aged society.[5-8]
Since the first diagnostic criteria for sarcopenia were announced in 2010, numerous basic and clinical research results have been reported globally.[9-12] Recent updates include the 2019 European Sarcopenia Diagnosis and Management Guidelines and the 2020 Asian Sarcopenia Diagnosis and Management Guidelines.[13-15] These guidelines provide comprehensive recommendations for the diagnosis and management of sarcopenia, highlighting the importance of early detection and intervention.
Sarcopenia has been assigned a disease code in the International Classification of Diseases, Eleven Revision, and since 2021, the diagnosis of sarcopenia (M62.5) has been included in the 8th Korean Standard Disease Cause Classification.[16] With the international consensus on the diagnostic algorithms and criteria, and recognition as an official disease, there has been a global focus on the importance and value of sarcopenia.[9,17-19] This recognition underscores the need for standardized diagnostic approaches and effective treatment strategies to manage this growing health issue.
Dual energy X-ray absorptiometry (DXA or DEXA) is considered the gold standard for diagnosing sarcopenia; however, there is a need for comparative studies using bioelectrical impedance analysis (BIA), particularly in the Korean population.[20-23] DXA provides precise measurements of bone density and body composition but is limited by its high cost and accessibility issues. In contrast, BIA is a more affordable and accessible option, making it a valuable tool for widespread screening in clinical and community settings.
This study aimed to evaluate the correlation between the concordance of limb muscle mass between Hologic and GE Lunar, whole-body bone density-measuring instruments, and InBody 970, a bioelectrical impedance-measuring instrument. By assessing these correlations, the study seeks to determine if BIA can serve as a reliable alternative to DXA. Furthermore, it is necessary to understand the validity of the bioelectrical impedance measurement method for the diagnosis of sarcopenia. Such validation is crucial for adopting BIA in clinical settings, particularly for widespread and cost-effective screening of sarcopenia.

METHODS

1. Participants

A total of 119 participants, aged 20 to 70 years old, with a body mass index (BMI) greater than or equal to 17 kg/m2 and less than or equal to 35 kg/m2 with a negative pregnancy test at the time of screening who voluntarily participated in the study and provided written consent were included (Approval no. 2106-029-468). During recruitment, 40 participants were selected for the 20 to 39 years age group, 40 participants for the 40 to 59 years age group, and 39 participants for the 60 to 70 years age group, with gender ratios and BMI ratios balanced and randomly sampled. The exclusion criteria were scoliosis, osteoarthritis, osteomalacia, or other clinical vertebral deformities; adverse events after previous DXA or radiography; pregnant or lactating women; those with artificial pacemakers or implanted cardiac pacemakers; and patients with mental illnesses, such as severe depression.
The Chung-Ang University Hospital Research Ethics Committee granted ethical approval for the study, and all participants provided their informed consent by signing a document prior to undergoing the scans.

2. DXA measurements

Each participant underwent two scans, utilizing both the Hologic QDR-4500W fan-beam DXA scanner (Hologic Inc., Bedford, MA, USA) and the GE-Lunar Prodigy DXA system (GE Medical Systems, Madison, WI, USA), in accordance with the standard scanning and positioning protocols specified by the respective manufacturers. Lines drawn through the glenohumeral joints separated the arms and trunk, while oblique lines through the hip joint, angled 45° from the body’s sagittal plane, divided the trunk and legs.[24] A transverse line below the mandible served to exclude the head from the trunk area, which encompassed the thorax, abdomen, pelvis, and a segment of the medial thigh.[24] The android region of interest (ROI) was demarcated at the lower boundary of the pelvis, with its upper boundary extending above the pelvic cut to include 20% of the distance to the neck cut, and bounded laterally by arm cuts.[24] The gynoid ROI’s upper limit was set at 1.5 times the height of the Android ROI below the pelvis, with a total height twice that of the Android ROI, and its lateral limits were defined by the external cuts of the legs.[24] To ensure uniformity across scans, manual ROI analysis was consistently carried out by the same experienced clinical densitometrists, certified by the International Society for Clinical Densitometry.[24]

3. BIA measurements

A single type of multi-frequency BIA (MF-BIA) machine, the InBody 970, was used to assess body composition. This machine measured the impedance of five body segments at frequencies of 1, 5, 50, 250, and 500 kHz, as well as at 1, 2, and 3 MHz. Participants were instructed to stand barefoot on the floor electrodes and grip the hand electrodes during the examination. Before electrode placement, each site was cleaned with an alcohol swab. Each measurement was performed twice and the mean value was used for subsequent analysis.

4. Statistical analyses

Statistical analysis was conducted to test the null hypothesis, which posited a correlation coefficient of 0.8 or higher between the two instruments for each measurement site. The sample size was calculated to require 116 participants by correcting the power according to the alternative hypothesis at a significance level and 80% of the power. The true (allowable) difference between the fat mass measurements was determined to be 1%, and the expected population standard deviation (SD) was 2% based on previous studies. The equivalence margin was set to 5%. Considering a final error rate of 5%, a total of 119 participants were selected as the final target group.[25] The sample size was determined using the website (http://riskcalc.org:3838/samplesize/).[25] The target group was recruited by distinguishing the distribution of age groups, BMI, and gender.
To evaluate accuracy, the study plotted differences between replicate DXA and BIA measurements from a given manufacturer against the estimated true value, employing Bland and Altman’s method for calculating agreement limits. The study utilized the concordance correlation coefficient to assess the precision and accuracy of the correlation between the two devices. Correlation coefficients were categorized as follows: 0.2 to 0.4 indicated weak correlation, 0.4 to 0.6 indicated moderate correlation, 0.6 to 0.8 indicated strong correlation, and 0.8 to 1.0 indicated very strong correlation.[26] For establishing the conversion formula, the relationship between DXA and BIA measurements was characterized using linear regression analysis. All statistical analyses were conducted using R Statistical Software (version 3.4.1; The R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

A total of 119 participants were recruited, considering their age, sex, and BMI ratio, as outlined in Table 1. The analysis was conducted in two main contexts.
When comparing the Inbody and DXA measurements, a meticulous assessment of the muscle mass was performed. This involved using BIA with the InBody 970 device and comparing the outcomes with whole-body DXA measurements obtained using the Hologic device. The investigation revealed robust correlation coefficients of 0.95 or higher across all extremities, indicating a strong linear relationship between the two methods, as shown in Table 2 and Figure 1. To gauge disparities, muscle mass readings obtained from the Hologic device were subtracted from those derived from the Inbody 970. These discrepancies were then presented as average values for both the left and right arms and for legs, including the maximum and minimum limit values (±1.96 SD). These values were visualized using Bland-Altman plots tailored to each distinct site (Fig. 2). The analysis demonstrated that a substantial proportion of the observed values fell within the ±1.96 SD range from the mean, highlighting the minimal differences between the two techniques.
Regarding the comparison between the InBody and GE Lunar measurements, the assessment of muscle mass involved comparing the BIA results obtained from the InBody 970 device with whole-body DXA measurements acquired using the GE Lunar device. The results indicated strong correlation coefficients of 0.93 or higher for most measurements, except for the right arm, which exhibited a correlation coefficient of 0.83, likely influenced by outliers (Table 3, Fig. 3). This underlines the substantial linear relationship between the Inbody and GE Lunar measurements. To quantify divergence, the differences in muscle mass were computed by subtracting the InBody 970 measurements from those obtained with the GE Lunar device. These divergences were then presented as average values for both the left and right arms and both legs, along with the maximum and minimum limit values (±1.96 SD). As in the previous phase, these findings were complemented by Bland-Altman plots tailored for each measurement site (Fig. 4). Similarly, a notable proportion of the results were within the ±1.96 SD range from the mean.
Additionally, the study summarized the muscle mass conversion formulas for different limb segments in Table 4 for the GE Lunar and Inbody 970 devices, and in Table 5 for the Hologic and InBody 970 devices.

DISCUSSION

The principal findings of this study were that the correlation between the muscle mass measured by the Hologic device and the GE Lunar device and the muscle mass measured by the Inbody 970 device was high and suggested a conversion formula that is important for the evaluation of sarcopenia between the mutual devices. To date, several cross-calibration studies on BIA and DXA have been reported.[27,28]
Yi et al. [21] conducted an analysis of the correlation between body composition measurements obtained from BIA (InBody 970) and GE Lunar equipment, particularly focusing on the agreement of appendicular lean mass, which showed a correlation of 0.95 or higher. These findings are consistent with our results, and in our study, we extended the analysis to include Hologic equipment. In addition, we provide conversion formulas that can be used in clinical settings. Analysis of skeletal muscle mass (whole-body or appendicular) plays an important role in evaluating patients for sarcopenia diagnosis, especially with the increasing global aging population. Although DXA is considered the gold standard for muscle mass measurement and shows a high correlation with magnetic resonance imaging (MRI), BIA is preferred owing to its non-invasiveness, cost-effectiveness, and comparability to more sophisticated imaging techniques such as computed tomography and MRI. However, it is crucial to note that BIA’s accuracy can be influenced by factors such as hydration status, recent food intake, and electrolyte balance, which can lead to variability in measurements. Also, the original single-frequency BIA had measurement errors related to body water status and BMI. To address these accuracy issues, BIA was later developed into MF-BIA and further expanded to direct segmental multi-BIA (DSM-BIA), enabling more precise measurements of each body part. MF-BIA also overcomes the accuracy issues by analyzing intracellular fluid impedance more accurately.
Nevertheless, measurements obtained through MF-BIA have shown varying degrees of accuracy compared with DXA or MRI, and different studies have reported differences in the rate of sarcopenia diagnosis. Several previous studies have evaluated the correlation between MF-BIA and DXA for assessing muscle mass, with some variation in the results depending on the measured portion (lean body mass, appendicular lean mass).[29-31] However, Fang et al. [31] demonstrated a strong correlation between MF-BIA and DXA in estimating muscle mass (r=0.969, P<0.001) among elderly individuals. Similarly, Jeon et al. [32] found a strong correlation between MF-BIA and DXA for muscle mass estimation (R2=0.914-0.917). Meier et al. [30] reported a correlation of 0.86 between DSM-BIA and DXA for muscle mass estimation after adjusting for age and sex. In the current study, we observed similar results in the same category, and we believe that MF-BIA could be useful in the management and diagnosis of sarcopenia.[30] Despite these correlations, the potential variability introduced by external factors like hydration status underscores the need for careful consideration when interpreting BIA results.
The research presented here encounters several constraints. Notably, there is a dearth of comparative studies on these devices, making it challenging to apply the study’s outcomes universally. However, the high correlation coefficients suggest that BIA, particularly the InBody 970, can be a reliable and more accessible alternative to DXA for muscle mass assessment. This is particularly important in settings where DXA may not be readily available or feasible. Furthermore, the conversion formula enables the standardization of muscle mass measurements across different devices, facilitating the comparison of results from various studies and clinical settings. This standardization can lead to more consistent diagnoses and monitoring of sarcopenia and other musculoskeletal conditions. To broaden the implications of these findings across different ethnicities, it is essential to conduct further research, particularly involving Caucasian subjects. Moreover, the study utilized a limited number of participants, which may impact the robustness and generalizability of the results. Future studies should aim to include larger, more diverse populations to validate these findings further and explore the impact of various physiological and external factors on BIA accuracy.
In conclusion, limb muscle mass measurements using Hologic and GE Lunar whole-body DXA and Inbody 970 BIA demonstrated a very high level of concordance. In addition, a conversion formula that bridges limb muscle mass measurements from two widely used whole-body DXA machines and a BIA machine will facilitate sarcopenia research and patient management.

DECLARATIONS

Funding

This research was supported by a fund (2021-11-007) by Research of Korea Disease Control and Prevention Agency.

Ethics approval and consent to participate

Ethical approval for the study was provided by the Chung-Ang University Hospital Research Ethics Committee, and informed signed consent was obtained from all participants before the scans were performed (Approval no. 2106-029-468).

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Fig. 1
Correlation coefficient for muscle mass between the InBody 970 and Hologic. (A) Right arm. (B) Left arm. (C) Right leg. (D) Left leg. BMC, bone mineral content.
jbm-2024-31-3-219f1.jpg
Fig. 2
Bland-Altman plots for muscle mass between the InBody 970 and Hologic. (A) Right arm. (B) Left arm. (C) Right leg. (D) Left leg. SD, standard deviation.
jbm-2024-31-3-219f2.jpg
Fig. 3
Correlation coefficient for muscle mass between the InBody 970 and GE Lunar. (A) Right arm. (B) Left arm. (C) Right leg. (D) Left leg. BMC, bone mineral content.
jbm-2024-31-3-219f3.jpg
Fig. 4
Bland-Altman plots for muscle mass between the InBody 970 and GE Lunar. (A) Right arm. (B) Left arm. (C) Right leg. (D) Left leg. SD, standard deviation.
jbm-2024-31-3-219f4.jpg
jbm-2024-31-3-219f5.jpg
Table 1
Recruitment status by age group and BMI of research participants
Variables Age (yr) Total

20-39 40-59 60-70
Male
 Normal (18.5 kg/m2 ≤ BMI ≤ 23 kg/m2) 10 10 9 29
 Obese (23.0 kg/m2 < BMI) 10 10 10 30

Female
 Normal (18.5 kg/m2 ≤ BMI ≤ 23 kg/m2) 10 10 10 30
 Obese (23.0 kg/m2 < BMI) 10 10 10 30

The data represent the number of patients.

BMI, body mass index.

Table 2
Correlation coefficient for muscle mass between the two devices (InBody 970 and Hologic)
Measurement area Correlation coefficient (95% CI)
Muscle mass right arm 0.960 (0.94-0.97)
Muscle mass left arm 0.954 (0.94-0.97)
Muscle mass right leg 0.954 (0.93-0.97)
Muscle mass left leg 0.956 (0.94-0.97)

CI, confidence interval.

Table 3
Correlation coefficient for muscle mass between the two devices (InBody 970 and GE Lunar)
Measurement area Correlation coefficient (95% CI)
Muscle mass right arm 0.827 (0.76-0.88)
Muscle mass left arm 0.935 (0.91-0.95)
Muscle mass right leg 0.959 (0.94-0.97)
Muscle mass left leg 0.926 (0.90-0.95)

CI, confidence interval.

Table 4
Conversion formula between InBody 970 and GE Lunar
Measurement area Conversion formula
Muscle mass right arm InBody_RA=0.8240×GE Lunar_RA+0.0001
Muscle mass left arm InBody_LA=0.9310×GE Lunar_LA+0.0015
Muscle mass right leg InBody_RL=0.9556×GE Lunar_RL+0.0023
Muscle mass left leg InBody_LL=0.9220×GE Lunar_LL+0.0007

To standardize the units of the observed values, Z-score normalization was performed.

RA, right arm; LA, left arm; RL, right leg; LL, left leg.

Table 5
Conversion formula between InBody 970 and Hologic
Measurement area Conversion formula
Muscle mass right arm InBody_RA=0.9559×Hologic_RA−0.0009
Muscle mass left arm InBody_LA=0.9500×Hologic_LA+0.0007
Muscle mass right leg InBody_RL=0.9499×Hologic_RL−0.0011
Muscle mass left leg InBody_LL=0.9525×Hologic_LL+0.0001

To standardize the units of the observed values, Z-score normalization was performed.

RA, right arm; LA, left arm; RL, right leg; LL, left leg.

REFERENCES

1. Voulgaridou G, Papadopoulou SD, Spanoudaki M, et al. Increasing muscle mass in elders through diet and exercise: a literature review of recent RCTs. Foods 2023;12:1218. https://doi.org/10.3390/foods12061218.
crossref pmid pmc
2. Liu X, Yue J. Precision intervention for sarcopenia. Precis Clin Med 2022;5:pbac013. https://doi.org/10.1093/pcmedi/pbac013.
crossref pmid pmc
3. Bianchetti A, Novelli A. Sarcopenia in the elderly: from clinical aspects to therapeutic options. Geriatr Care 2019;5:8033. https://doi.org/10.4081/gc.2019.8033.
crossref
4. Povoroznyuk VV, Dedukh NV, Bystrytska MA, et al. The association of sarcopenia and osteoporosis and their role in falls and fractures: literature review. Med Perspekt 2021;26:111-9. https://doi.org/10.26641/2307-0404.2021.2.234637.
crossref
5. Park S, Nam JY. Effects of changes in multiple chronic conditions on medical costs among older adults in South Korea. Healthcare (Basel) 2022;10:742. https://doi.org/10.3390/healthcare10040742.
crossref pmid pmc
6. Kim M, Kim S, Suh HS. Economic burden of opioid misuse focused on direct medical costs. Front Pharmacol 2022;13:928890. https://doi.org/10.3389/fphar.2022.928890.
crossref pmid pmc
7. Garg R, Cheng V, Ellis U, et al. Direct medical costs of young-onset colorectal cancer: a worldwide systematic review. BMC Health Serv Res 2022;22:1100. https://doi.org/10.1186/s12913-022-08481-6.
crossref pmid pmc
8. Li D, Su M, Guo X, et al. The effect of medical choice on health costs of middle-aged and elderly patients with chronic disease: based on principal-agent theory. Int J Environ Res Public Health 2022;19:7570. https://doi.org/10.3390/ijerph19137570.
crossref pmid pmc
9. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:601. https://doi.org/10.1093/ageing/afz046.
crossref pmid pmc
10. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010;116:e35-40. https://doi.org/10.1182/blood-2010-04-280347.
crossref pmid pmc
11. Sherlin L, Arns M, Lubar J, et al. A position paper on neurofeedback for the treatment of ADHD. J Neurother 2010;14:66-78. https://doi.org/10.1080/10874201003773880.
crossref
12. Leckman JF, Denys D, Simpson HB, et al. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety 2010;27:507-27. https://doi.org/10.1002/da.20669.
crossref pmid pmc
13. Won CW. Management of sarcopenia in primary care settings. Korean J Fam Med 2023;44:71-5. https://doi.org/10.4082/kjfm.22.0224.
crossref pmid pmc
14. Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. https://doi.org/10.1111/hepr.13678.
crossref pmid
15. O’Callaghan S, Quinn S, Digan E, et al. A clinical audit of detection and management of sarcopenia in older persons’ specialist rehabilitation services in an academic teaching hospital. Age Ageing 2019;48:Suppl 3. iii17-iii65. https://doi.org/10.1093/ageing/afz103.150.
crossref
16. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016;7:512-4. https://doi.org/10.1002/jcsm.12147.
crossref pmid pmc
17. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 2022;15:321-35. https://doi.org/10.1159/000521241.
crossref pmid pmc
18. Donato B, Fernandes AP, Raimundo M, et al. The evaluation of sarcopenia in non-dialysis chronic kidney disease stages by computed tomography. Nephrol Dial Transplant 2021;36:Suppl 1. gfab089.04. https://doi.org/10.1093/ndt/gfab089.004.
crossref
19. Kamiya K, Hamazaki N, Matsuzawa R, et al. Sarcopenia: prevalence and prognosis in older patients with cardiovascular disease. Innov Aging 2017;1(Suppl 1):599. https://doi.org/10.1093/geroni/igx004.2097.
crossref pmc
20. Chen M, Liu J, Ma Y, et al. Association between body fat and elevated blood pressure among children and adolescents aged 7-17 years: using dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA) from a cross-sectional study in China. Int J Environ Res Public Health 2021;18:9254. https://doi.org/10.3390/ijerph18179254.
crossref pmid pmc
21. Yi Y, Baek JY, Lee E, et al. A comparative study of high-frequency bioelectrical impedance analysis and dual-energy X-ray absorptiometry for estimating body composition. Life (Basel) 2022;12:994. https://doi.org/10.3390/life12070994.
crossref pmid pmc
22. Samouda H, Langlet J. Body fat assessment in youth with overweight or obesity by an automated bioelectrical impedance analysis device, in comparison with the dual-energy x-ray absorptiometry: a cross sectional study. BMC Endocr Disord 2022;22:195. https://doi.org/10.1186/s12902-022-01111-6.
crossref pmid pmc
23. Lahav Y, Goldstein N, Gepner Y. Comparison of body composition assessment across body mass index categories by two multifrequency bioelectrical impedance analysis devices and dual-energy X-ray absorptiometry in clinical settings. Eur J Clin Nutr 2021;75:1275-82. https://doi.org/10.1038/s41430-020-00839-5.
crossref pmid
24. Ha YC, Yoo JI. Cross-calibration of bone mineral densities and body composition between GE lunar prodigy and osteosys primus. J Bone Metab 2021;28:215-21. https://doi.org/10.11005/jbm.2021.28.3.215.
crossref pmid pmc
25. Wang X, Ji X. Sample size estimation in clinical research: From randomized controlled trials to observational studies. Chest 2020;158:S12-s20. https://doi.org/10.1016/j.chest.2020.03.010.
crossref pmid
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
crossref pmid
27. Hsieh KC, Lu HK, Chen CH, et al. The validity and accuracy in foot-to-foot bioelectrical impedance analysis measuring models referenced by dual-energy X-ray absorptiometry in body composition in standing position. Afr J Biotechnol 2011;10:3222-31. https://doi.org/10.5897/AJB10.1132.
crossref
28. Malavolti M, Mussi C, Poli M, et al. Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol 2003;30:380-91. https://doi.org/10.1080/0301446031000095211.
crossref pmid
29. Kim M, Shinkai S, Murayama H, et al. Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body composition in a community-dwelling older population. Geriatr Gerontol Int 2015;15:1013-22. https://doi.org/10.1111/ggi.12384.
crossref pmid
30. Meier NF, Bai Y, Wang C, et al. Validation of a multielectrode bioelectrical impedance analyzer with a dual-energy X-ray absorptiometer for the assessment of body composition in older adults. J Aging Phys Act 2020;28:598-604. https://doi.org/10.1123/japa.2019-0211.
crossref pmid
31. Fang WH, Yang JR, Lin CY, et al. Accuracy augmentation of body composition measurement by bioelectrical impedance analyzer in elderly population. Medicine (Baltimore) 2020;99:e19103. https://doi.org/10.1097/md.0000000000019103.
crossref pmid pmc
32. Jeon KC, Kim SY, Jiang FL, et al. Prediction equations of the multifrequency standing and supine bioimpedance for appendicular skeletal muscle mass in Korean older people. Int J Environ Res Public Health 2020;17:5847. https://doi.org/10.3390/ijerph17165847.
crossref pmid pmc
TOOLS
METRICS Graph View
  • 1 Crossref
  •  0 Scopus 
  • 1,092 View
  • 47 Download
ORCID iDs

Yong-Chan Ha
https://orcid.org/0000-0002-6249-0581

Shinjune Kim
https://orcid.org/0009-0004-9570-7830

Jun-Il Yoo
https://orcid.org/0000-0002-3575-4123

Related articles


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Hyundai Kirim Officetel, 42 Seocho-daero 78-gil, Seocho-gu, Seoul 06626, Korea
Tel: +82-2-3473-2231    Fax: +82-70-4156-2230    E-mail: jbm@ksbmr.org                

Copyright © 2024 by The Korean Society for Bone and Mineral Research.

Developed in M2PI

Close layer
prev next